Natalizumab inhibits the influx of leukocytes into the central nervous system (CNS) via blockade of alpha-4 subunit of very late activation antigen (VLA)-4. The association of natalizumab therapy with progressive multifocal leukoencephalopathy (PML) suggests a disturbance of CNS immune surveillance in a small percentage of Multiple Sclerosis (MS) patients exposed to the medication. Natural killer (NK) cells are known to play an important role in modulating the evolution of different phases of this lymphocyte mediated disease, and we investigated the effects of natalizumab on the NK cell phenotype and infiltration in the CNS in experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Our data show that both resting (from naïve mice) and activated (from EAE mice) NK cells express high levels of VLA-4, and anti-VLA-4 antibody treatment significantly decreases NK cells frequency in the CNS of EAE mice. Moreover, we find that anti-VLA-4 possibly impairs NK cells migratory potential, since unblocked VLA-4 expression levels were downregulated on those NK cells that penetrate the CNS. These data suggest that treatment with antibody to VLA-4 may alter immune surveillance of the CNS by impacting NK cell functions and might contribute to the understanding of the mechanisms leading to the development of PML in some MS patients.
Introduction
Designed on the basis of progenitor antibodies capable of preventing leukocyte accumulation in the central nervous system (CNS) of experimental autoimmune encephalomyelitis (EAE, the mouse model of multiple sclerosis) (Yednock et al., 1992; Kent et al., 1995) , natalizumab (Tysabri®) is the first humanized monoclonal antibody approved for treatment of the relapsing-remitting form of multiple sclerosis (MS) (Miller et al., 2003; Biogen Idec, 2011) . It selectively binds to the alpha-4 integrin subunit of very late activation antigen-4 (VLA-4, alpha-4/beta-1 integrin) on immune cells, and inhibits transmigration of autoreactive cells across the blood-brain barrier into CNS by blocking the interaction of lymphocyte VLA-4 with its endothelial ligand vascular cell adhesion molecule 1 (VCAM-1) (von Andrian and Engelhardt, 2003) . Unfortunately, the impressive efficacy in reducing relapse rates and disease progression obtained in MS patients with this medication (Polman et al., 2006) , has been counterbalanced by the association of the use of natalizumab with the occurrence of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal demyelinating disease caused by JC virus (JCV) (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al., 2005; Biogen Idec, 2011) .
A relationship between duration of therapy with natalizumab and prior exposures to other chemotherapies to treat their MS, have been established as increased risk factors for the development of PML (Biogen Idec, 2011; Kappos et al., 2011) . Thus, it is likely that treatment with natalizumab results in impaired immune surveillance of the CNS in an overall small percentage of patients, and the potential for an immune-suppression specific to the CNS could be related to the effects of the drug on particular immune cells subsets. Evidence from studies in patients has shown that natalizumab induces a sustained decrease in immune cell (T and B cells) numbers in the cerebrospinal fluid (CSF) (Stüve et al., 2006) as well as depletion of dendritic cells in cerebral perivascular spaces (del Pilar Martin et al., 2008) . Inhibition of T-cell trafficking is thought to underlie both drug efficacy and its potential toxicity. However, the impact on other cell subsets may be relevant and we were interested in evaluating natural killer (NK) cells because of their described immunosuppressive activity, the reduced levels detected in MS subjects (Segal, 2007) , and the accelerated onset and increased severity of MOG peptide induced EAE in NK-depleted mice (Zhang et al., 1997) . CD56 + NK cells were reported to increase in peripheral blood of patients after natalizumab treatment (Skarica et al., 2011 ) that might be part of the mechanism of action of natalizumab. Despite considerable efforts and in part due to limitations from methodologies, the biological activity of NK cells in the CNS during exposure to natalizumab is poorly understood. Considering that VLA-4 was demonstrated to be expressed in human NK cells (Gismondi et al., 1991; Macías et al., 2000) , we Journal of Neuroimmunology 247 (2012) 9-15 
